text stringlengths 1 5.46k |
|---|
Title Country Application No. Filed Priority Date Status |
Interleukin-2 Variants And Methods Of Uses Thereof AUSTRALIA 2019288496 6/20/2019 12/16/2020 6/22/2018 Pending |
Interleukin-2 Variants And Methods Of Uses Thereof CANADA 3,102,829 6/20/2019 12/4/2020 6/22/2018 Pending |
Interleukin-2 Variants And Methods Of Uses Thereof CHINA 201980054901 6/20/2019 6/22/2018 Pending |
Interleukin-2 Variants And Methods Of Uses Thereof EPC 19821901.6 6/20/2019 1/12/2021 6/22/2018 Pending |
Interleukin-2 Variants And Methods Of Uses Thereof JAPAN 2021-520278 6/20/2019 12/18/2020 6/22/2018 Pending |
Interleukin-2 Variants And Methods Of Uses Thereof KOREA 10-2021-7002153 6/20/2019 01/21/2021 6/22/2018 Pending |
Interleukin-2 Variants And Methods Of Uses Thereof MEXICO MX/a/2020/014296 6/20/2019 12/18/2020 6/22/2018 Pending |
Interleukin-2 Variants And Methods Of Uses Thereof UNITED STATES 17/254,098 6/20/2019 12/18/2020 6/22/2018 Pending |
Interleukin-2 Variants And Methods Of Uses Thereof UNITED STATES 62/689,055 6/22/2018 N/A Closed |
Interleukin-2 Variants And Methods Of Uses Thereof UNITED STATES 62/755,016 11/2/2018 N/A Closed |
Interleukin-2 Variants And Methods Of Uses Thereof WIPO PCT/US2019/038248 6/20/2019 6/22/2018 Closed |
Title Country Application No. Filed Priority Date Status |
Novel Interleukin-2 Variants For The Treatment Of Cancer AUSTRALIA 2020291942 6/13/2020 12/22/2021 6/14/2019 Pending |
Novel Interleukin-2 Variants For The Treatment Of Cancer CANADA 3143034 6/13/2020 12/08/2021 6/14/2019 Pending |
Novel Interleukin-2 Variants For The Treatment Of Cancer CHINA N/A 6/13/2020 6/14/2019 Pending |
Novel Interleukin-2 Variants For The Treatment Of Cancer EPC 20823471.6 6/13/2020 1/4/2022 6/14/2019 Pending |
Novel Interleukin-2 Variants For The Treatment Of Cancer JAPAN 2021573421 6/13/2020 12/10/2021 6/14/2019 Pending |
Novel Interleukin-2 Variants For The Treatment Of Cancer KOREA 10-2022-7001353 6/13/2020 01/13/2022 6/14/2019 Pending |
Novel Interleukin-2 Variants For The Treatment Of Cancer MEXICO MX/a/2021/015834 6/13/2020 12/15/2021 6/14/2019 Pending |
Novel Interleukin-2 Variants For The Treatment Of Cancer NEW ZEALAND 783836 6/13/2020 12/22/2021 6/14/2019 Pending |
Novel Interleukin-2 Variants For The Treatment Of Cancer RUSSIA 2021139059 6/13/2020 12/27/2021 6/14/2019 Pending |
Novel Interleukin-2 Variants For The Treatment Of Cancer UNITED STATES 17/618,140 6/13/2020 12/10/2021 6/14/2019 Pending |
Novel Interleukin-2 Variants For The Treatment Of Cancer UNITED STATES 62/861,651 6/14/2019 N/A Closed |
Novel Interleukin-2 Variants For The Treatment Of Cancer UNITED STATES 62/947,806 12/13/2019 N/A Closed |
Novel Interleukin-2 Variants For The Treatment Of Cancer WIPO PCT/US2020/037644 6/13/2020 6/14/2019 Closed |
Title Country Application No. Filed Priority Date Status |
Novel Interleukin-2 Variants And Bifunctional Fusion Molecules Thereof AUSTRALIA 2020292421 6/13/2020 12/22/2021 6/14/2019 Pending |
Novel Interleukin-2 Variants And Bifunctional Fusion Molecules Thereof CANADA 3143038 6/13/2020 12/08/2021 6/14/2019 Pending |
Novel Interleukin-2 Variants And Bifunctional Fusion Molecules Thereof CHINA N/A 6/13/2020 6/14/2019 Pending |
Novel Interleukin-2 Variants And Bifunctional Fusion Molecules Thereof EPC 20823570.5 6/13/2020 01/04/2022 6/14/2019 Pending |
Novel Interleukin-2 Variants And Bifunctional Fusion Molecules Thereof JAPAN 2021-573426 6/13/2020 12/10/2021 6/14/2019 Pending |
Novel Interleukin-2 Variants And Bifunctional Fusion Molecules Thereof KOREA 10-2022-700354 6/13/2020 01/13/2022 6/14/2019 Pending |
Novel Interleukin-2 Variants And Bifunctional Fusion Molecules Thereof UNITED STATES 17/608,207 6/13/2020 12/10/2021 6/14/2019 Pending |
Novel Interleukin-2 Variants And Bifunctional Fusion Molecules Thereof UNITED STATES 62/861,484 6/14/2019 N/A Closed |
Novel Interleukin-2 Variants And Bifunctional Fusion Molecules Thereof WIPO PCT/US2020/037648 6/13/2020 6/14/2019 Closed |
SCHEDULE 1.116 |
IN-LICENSE SCHEDULE |
WuXi Agreement |
SCHEDULE 1.123 |
INDICATIONS |
The following would be treated as separate Indications: |
• Systemic Lupus Erythematosus |
• Lupus Nephritis |
• Type I diabetes |
• Type II diabetes |
• Atopic Dermatitis |
• Ulcerative Colitis |
• Crohn's disease |
• Psoriasis |
• Rheumatoid Arthritis |
• Ankylosing Spondylitis |
• Sjogren's syndrome |
• Behcet's disease |
• Sclerosing cholangitis |
• Granulomatosis with polyangiitis |
• Takayasu's disease |
• Autoimmune hepatitis |
• Allergic Anaphylaxis |
• Alopecia Areata |
• ANCA Vasculitis |
• Celiac Disease |
• Chronic Fibrosing Lung Disease |
• COVID-19 |
• Dermatomyositis |
• Graft Versus Host Disease |
• Hidradenitis Suppurativa |
• IgG4-related Systemic Disease |
• Idiopathic Pulmonary Fibrosis |
• Multiple Sclerosis |
• Primary Biliary Cirrhosis |
• Polymyositis |
• Psoriatic Arthritis |
• Systemic Sclerosis (including Systemic Sclerosis-associated Lung Disease) |
• Vitiligo |
SCHEDULE 1.126 |
INITIAL DEVELOPMENT PLAN AND BUDGET |
AbbVie contributors/principal owners: Discovery Raj Kamath |
Development Alan Friedman |
DMPK James Sheridan |
CPPM Wei Liu |
DMPK/ Toxicology Kennan Marsh, David Honor |
Stats Zailong Wang |
Biologics Discovery Blaine Stine |
CMC – R&D John Morris, Hans_Juergen Krause, Omon Herigstad |
Project Management Shelly Ziemelis |
CSL Rachele Jareb |
IP Sonali Srivastava |
BD Jake Cournoyer |
S&E Gordon Ng |
Regulatory Lee Muraoka |
OVERALL PLANS AND GOALS |
Completion of the CUG252 Phase I Clinical Trial reported in the USA FDA IND 152972 following FDA notice to proceed (dated November 12, 2021) |
The overall objective of this development plan is to assess the therapeutic potential, safety, PK-PD of CUG252 in a first-in-human Single Ascending Dose (SAD) Phase Ia Clinical Trial in healthy volunteers (HV), explore in an early proof of concept (ePoC) Multiple Ascending Dose (MAD) Phase Ib Clinical Trial in adult pa... |
The following Gantt chart describes the key clinical, pre-clinical, and CMC activities that will be performed as part of the Initial Development Plan and Budget as defined in that certain Collaboration and License Option Agreement, dated May 6, 2022 (Agreement) between AbbVie Global Enterprises Ltd. (AbbVie) and Cugene... |
CUG252 Development Plan Gantt Chart |
[Chart described but not fully visible in text form] |
I. ADMINISTRATION/OPERATIONS |
A. Monthly Updates and Quarterly Reporting at Least Through Start-Up |
Monthly meeting updates are to contain the following as available: |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.